Novartis AG (NYSE:NVS) has been assigned a consensus rating of “Hold” from the fourteen brokerages that are presently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $85.39.
Several equities analysts have recently issued reports on NVS shares. Zacks Investment Research lowered shares of Novartis from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Bank of America lowered shares of Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. UBS Group reaffirmed a “neutral” rating on shares of Novartis in a research report on Monday, January 15th. Nord/LB reaffirmed a “neutral” rating on shares of Novartis in a research report on Wednesday, December 27th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novartis in a research report on Thursday, January 18th.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Wealthcare Advisory Partners LLC bought a new stake in Novartis in the 3rd quarter valued at $106,000. Pinnacle Wealth Planning Services Inc. bought a new stake in Novartis in the 4th quarter valued at $113,000. Calton & Associates Inc. bought a new stake in Novartis during the 4th quarter worth about $118,000. SeaCrest Wealth Management LLC bought a new stake in Novartis during the 4th quarter worth about $124,000. Finally, Trustcore Financial Services LLC bought a new stake in Novartis during the 4th quarter worth about $178,000. 10.80% of the stock is currently owned by institutional investors and hedge funds.
Novartis (NYSE:NVS) last announced its quarterly earnings results on Wednesday, January 24th. The company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.04. Novartis had a net margin of 15.69% and a return on equity of 16.03%. The company had revenue of $12.92 billion during the quarter, compared to analyst estimates of $12.65 billion. During the same quarter in the previous year, the business earned $1.14 EPS. The firm’s revenue was up 4.8% on a year-over-year basis. sell-side analysts predict that Novartis will post 5.36 earnings per share for the current year.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.